aussie her3, can confirm bnuuy moment
March 31, 2026 at 1:03 PM
aussie her3, can confirm bnuuy moment
Insightful discussion of targeting HER3 by @lilliansiu.bsky.social at #ASCO25
May 30, 2025 at 8:43 PM
Insightful discussion of targeting HER3 by @lilliansiu.bsky.social at #ASCO25
well-timed review on HER3 in cancer by Helena Yu (from @mskcancercenter.bsky.social @mskdeptofmed.bsky.social ) and colleagues. Multiple HER3 antibody-drug conjugates in development.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Emerging importance of HER3 in tumorigenesis and cancer therapy - Nature Reviews Clinical Oncology
HER3 is emerging as a promising therapeutic target that is often overexpressed or genetically altered across diverse solid tumour types. This Review describes the landscape of HER3 alterations in canc...
www.nature.com
April 7, 2025 at 4:41 PM
well-timed review on HER3 in cancer by Helena Yu (from @mskcancercenter.bsky.social @mskdeptofmed.bsky.social ) and colleagues. Multiple HER3 antibody-drug conjugates in development.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Her3 comes the dump
Here comes the dump
Everyone is ready for tha....
Doo~o~dle dump!
Featuring 🥁
A mouse pad and a mouse having diaper set
Vex
And a Stinky Skitty
Here comes the dump
Everyone is ready for tha....
Doo~o~dle dump!
Featuring 🥁
A mouse pad and a mouse having diaper set
Vex
And a Stinky Skitty
June 30, 2026 at 5:24 AM
Her3 comes the dump
Here comes the dump
Everyone is ready for tha....
Doo~o~dle dump!
Featuring 🥁
A mouse pad and a mouse having diaper set
Vex
And a Stinky Skitty
Here comes the dump
Everyone is ready for tha....
Doo~o~dle dump!
Featuring 🥁
A mouse pad and a mouse having diaper set
Vex
And a Stinky Skitty
March 6, 2025 at 6:06 PM
My phone keyboard is so laggy that I often will have 3's in the place of e's
Ex: Her3; H3llo; f3bruary
Ex: Her3; H3llo; f3bruary
September 13, 2025 at 8:14 PM
My phone keyboard is so laggy that I often will have 3's in the place of e's
Ex: Her3; H3llo; f3bruary
Ex: Her3; H3llo; f3bruary
October 17, 2024 at 8:15 AM
HER3-Targeted Antibody-Drug Conjugate Shows Promise for Treatment-Resistant Solid Tumors
@ascocancer.bsky.social
oncodaily.com/insight/anti...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ADC #HER3 #SolidTumors #NSCLC #LungCancer #DB1310 #ASCO #ASCO2025
@ascocancer.bsky.social
oncodaily.com/insight/anti...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ADC #HER3 #SolidTumors #NSCLC #LungCancer #DB1310 #ASCO #ASCO2025
HER3-Targeted Antibody-Drug Conjugate Shows Promise for Treatment-Resistant Solid Tumors - OncoDaily
HER3-Targeted Antibody-Drug Conjugate Shows Promise for Treatment-Resistant Solid Tumors / Aaron Lisberg, ADC, Alex Spira, Alexander Starodub, American
oncodaily.com
May 30, 2025 at 8:40 PM
HER3-Targeted Antibody-Drug Conjugate Shows Promise for Treatment-Resistant Solid Tumors
@ascocancer.bsky.social
oncodaily.com/insight/anti...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ADC #HER3 #SolidTumors #NSCLC #LungCancer #DB1310 #ASCO #ASCO2025
@ascocancer.bsky.social
oncodaily.com/insight/anti...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ADC #HER3 #SolidTumors #NSCLC #LungCancer #DB1310 #ASCO #ASCO2025
Now online - Article
"Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1–HER3 signaling"
✏️by Roberto Würth & Andreas Trumpp and team
🔗https://www.nature.com/articles/s43018-024-00882-2?utm_source=bluesky&utm_medium=social&utm_campaign=natcancer
"Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1–HER3 signaling"
✏️by Roberto Würth & Andreas Trumpp and team
🔗https://www.nature.com/articles/s43018-024-00882-2?utm_source=bluesky&utm_medium=social&utm_campaign=natcancer
Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1–HER3 signaling - Nature Cancer
Trumpp and colleagues develop a method to obtain long-term circulating tumor cell-derived organoids from individuals with metastatic breast cancer and identify the neuregulin 1–HER3 axis as important ...
www.nature.com
January 8, 2025 at 12:11 PM
Now online - Article
"Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1–HER3 signaling"
✏️by Roberto Würth & Andreas Trumpp and team
🔗https://www.nature.com/articles/s43018-024-00882-2?utm_source=bluesky&utm_medium=social&utm_campaign=natcancer
"Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1–HER3 signaling"
✏️by Roberto Würth & Andreas Trumpp and team
🔗https://www.nature.com/articles/s43018-024-00882-2?utm_source=bluesky&utm_medium=social&utm_campaign=natcancer
There's a lot of replies her3, but someone BETTER have tagged @thelouvreof.bsky.social for this
August 1, 2025 at 9:42 PM
There's a lot of replies her3, but someone BETTER have tagged @thelouvreof.bsky.social for this
A lovely little pre christmas treat from @not-her3.bsky.social
December 22, 2024 at 3:44 PM
A lovely little pre christmas treat from @not-her3.bsky.social
April 1, 2025 at 1:58 PM
if ur a part of the queer community i luv u n her3 is a kiss 4 u 😘😘😘😘
June 2, 2025 at 3:03 AM
if ur a part of the queer community i luv u n her3 is a kiss 4 u 😘😘😘😘
October 20, 2024 at 12:30 AM
Here her3. Thanks @notmrtibbs.com
Let us all make sure we give thanks for the amazing work from @notmrtibbs.com and his team during HOF SZN.
January 20, 2026 at 11:54 PM
Here her3. Thanks @notmrtibbs.com
People don’t read signs. You could have a big ass sign plastered on your window in bold letters saying “WE DON’T DO THIS HERE” and someone will still stroll up like “dO u d0 tHis hEr3???”
August 13, 2025 at 1:03 PM
People don’t read signs. You could have a big ass sign plastered on your window in bold letters saying “WE DON’T DO THIS HERE” and someone will still stroll up like “dO u d0 tHis hEr3???”
Ciencia cuando ya no queda nada más: "Investigamos un medicamento para personas con metástasis cerebral"
Ciencia cuando ya no queda nada más: "Investigamos un medicamento para personas con metástasis cerebral"
La empresa española MEDSIR estudia los prometedores efectos de un medicamento que se llama HER3-DXd con el que, en las pruebas, 1 de cada 3 pacientes con metástasis cerebral "mantuvieron e incluso mejoraron sus capacidades cognitivas durante el tratamiento"
dozz.es
July 7, 2025 at 1:11 PM
Ciencia cuando ya no queda nada más: "Investigamos un medicamento para personas con metástasis cerebral"
Hey peeps. Just checking in. I am in a pretty bad way, just about surviving. My mum and cats keep me going; her3 are pictures of the latter 😍 I hope you're all ok
September 18, 2026 at 10:15 PM
Hey peeps. Just checking in. I am in a pretty bad way, just about surviving. My mum and cats keep me going; her3 are pictures of the latter 😍 I hope you're all ok
🆕study in Nature Cancer uncovers how circulating tumor cell (#CTC) plasticity drives therapy resistance in metastatic #breastcancer via the NRG1–HER3 axis. Dual blockade of 🎯 NRG1–HER3 & FGFR1 signaling offers a path to #PrecisionMedicine.
Read more: buff.ly/3Pniny0
Read more: buff.ly/3Pniny0
January 6, 2025 at 12:22 PM
🆕study in Nature Cancer uncovers how circulating tumor cell (#CTC) plasticity drives therapy resistance in metastatic #breastcancer via the NRG1–HER3 axis. Dual blockade of 🎯 NRG1–HER3 & FGFR1 signaling offers a path to #PrecisionMedicine.
Read more: buff.ly/3Pniny0
Read more: buff.ly/3Pniny0
A basket study evaluated the efficacy of zenocutuzumab, a bispecific antibody against HER2 and HER3, in patients with solid tumors harboring NRG1 fusions. Among 158 patients, 30% had a response (including 42% with pancreatic cancer). Full eNRGy study results: nej.md/40HAQut
#MedSky #Oncology
#MedSky #Oncology
Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer | NEJM
Neuregulin 1 (NRG1) fusions are recurrent oncogenic drivers found in multiple solid
tumors. NRG1 binds to human epidermal growth factor receptor 3 (HER3), leading to
heterodimerization with HER2 an...
nej.md
February 6, 2025 at 5:23 PM
A basket study evaluated the efficacy of zenocutuzumab, a bispecific antibody against HER2 and HER3, in patients with solid tumors harboring NRG1 fusions. Among 158 patients, 30% had a response (including 42% with pancreatic cancer). Full eNRGy study results: nej.md/40HAQut
#MedSky #Oncology
#MedSky #Oncology
The HER2/HER3-targeted bispecific antibody zenocutuzumab was associated with a 37% overall response rate in patients with a rare cholangiocarcinoma enrolled in the eNRGy phase II clinical trial, as reported at #Targets25. buff.ly/2ef2d6n
October 26, 2025 at 1:27 PM
The HER2/HER3-targeted bispecific antibody zenocutuzumab was associated with a 37% overall response rate in patients with a rare cholangiocarcinoma enrolled in the eNRGy phase II clinical trial, as reported at #Targets25. buff.ly/2ef2d6n
A couple of cocktails & food with @not-her3.bsky.social before watching Nosferatu x
January 17, 2025 at 5:46 PM
A couple of cocktails & food with @not-her3.bsky.social before watching Nosferatu x
Same. Can't stomach using X and giving Elmo value for my views. Will be just her3 for the foreseeable future.
November 6, 2024 at 7:04 PM
Same. Can't stomach using X and giving Elmo value for my views. Will be just her3 for the foreseeable future.